For professionals
Memory Clinic
At ReMind UK we welcome both NHS and private referrals to our memory clinic. Patients are usually referred by their GP with a suspicion of memory problems. GPs are asked to complete the following tests before referral to ReMind UK:
- ReMind UK require recent full blood count, renal and liver function, calcium, glucose and cholesterol test, and that thyroid function, B12 and folate levels are normal before referral.
- For BANES GP’s use the ReMind UK blood profile on ICE.
- We also require a CT head scan.
Resources for professionals:
Tell your patients about our new Guide to Living Well with Dementia. A collection of advice, tips and signposting to services in BANES. Created by our psychological support team with patients and their carers in mind.
Print out one of ReMind UK’s leaflets for your patients to take away with them and read.
Dementia research
ReMind UK actively explores all aspects of ageing well, including how we might use drug treatments more safely in older people. A major focus of our clinical research is exploring the way in which people respond to treatments when they get older, including when dementia such as Alzheimer’s disease develops. Our purpose-built research centre, located at The Royal United Hospital (RUH) site in Bath, has facilities for clinical studies, and is particularly well suited for clinical trials exploring new drug treatments for dementia and memory decline. The ReMind UK centre is fully equipped for pharmacokinetic studies and has an experienced team of medical, nursing, psychology and research staff.
Current dementia research studies open for patient referrals:
Please get in touch with ReMind UK in order to refer a patient for any of the dementia research or Alzheimer’s disease clinical trials listed below. We are actively recruiting for these studies.
The ReTain clinical research study is for adults who are concerned about their risk of developing Alzheimer’s disease. Participants must be currently healthy with no cognitive impairment. The trial will assess the effect of an immunotherapy medication on cognitive decline, this medication will be given by injection to the arm.
Eligibility requirements:
- No diagnosis (preclinical AD)
- Age 55-75
- MMSE (Mini-Mental State Examination) score of 27 and over
- Able to undergo MRI and PET scans
Phase 3 research trial to assess the safety and efficacy of donanemab infusions in participants with early Alzheimer’s disease.
Eligibility requirements:
- 60-85 years old
- Diagnosis of Mild Cognitive Impairment, or Mild Alzheimer’s disease, or no diagnosis but gradual/progressive memory changes for 6 months or more.
- MMSE (Mini-Mental State Examination) score of 20-28 inclusive.
- Able to undergo MRI and PET scans.
Randomised double-blind clinical trial to investigate whether an antibody called ‘IBC-Ab002’ has the potential to help slow cognitive decline in patients with early Alzheimer’s disease.
Eligibility requirements:
- 50-80 years old
- Diagnosis of Mild Cognitive Impairment or Mild Alzheimer’s disease
- MMSE (Mini-Mental State Examination) score of 20-28 inclusive
- On stable dose of AChE Inhibitor (donepezil, galantamine or rivastigimine) or memantine for at least 3 months prior to randomisation, or not taking an AChE Inhibitor
- Has a family member, friend or carer willing to act as Study Partner (in contact with participant minimum of 15 hours per week)
- Able to undergo MRI scan, lumbar puncture and EEG (electroencephalogram)
Looking at whether prebiotic supplementation improves skeletal muscle health in older adults.
Eligibility requirements:
- 65-85 years old
- Participants should be able to rise from a chair without using arms.
Exclusion criteria:
- Consumption of products marketed as prebiotics, probiotics (healthy bacteria that reaches the gut) or synbiotics (a combination of pre- and probiotics) within 4 weeks prior to study entry (e.g. Yakult, Actimel, Activia, VSL#3, Kefir). Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion.
- Taking systemic antibiotic or antimycotic treatment within 6 weeks prior to study entry.
- Following a diet likely to affect study outcomes: e.g. low FODMAP (fermentable oligo-, di-, mono-saccharides and polyols), Keto/high-fat, gluten free/coeliac, paleo, weight loss, caloric restriction, low-carb, 5:2/whole day energy restriction, Atkins/high protein, sugar-free, single-food, juicing/any day of juicing, any other restriction diet (e.g. very low calorie), or vegan diets (Bimuno is derived from cow’s milk).
- Meeting the physical activity guidelines for older adults: Activities that improve strength, flexibility and balance at least two days per week. At least 150 minutes of moderate-intensity activity, or 75 minutes of vigorous activity per week
- Body weight loss of greater than or equal to 5% in preceding 6 months
- History of injury or surgery that would affect physical ability to undertake physical tests
- History of gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome).
A research project to develop a new way of diagnosing dementia earlier. Healthy volunteers (without a dementia diagnosis) can take part even if they participated in previous FASTBALL studies.
Eligibility requirements:
- Aged 55+
- Participants must be willing to have an EEG testing session either at home or the University of Bath.
Exclusion criteria:
- You have a neurological disorder
- You have a known history of epilepsy or seizures
- You have ever experienced discomfort or adverse reactions to flickering visual/light stimuli
- You have experienced any unexplained episodes of feeling faint and/or confused
- You have a history of epilepsy in your family